Mar 1, 2025 · To evaluate enteral and parenteral anticoagulant and antiplatelet medications and their associated risks of hematuria-related complications. This was a single-institution, …

Sep 1, 2007 · Les anomalies hémostatiques le plus souvent observées sont une diminution de l'agrégabilité et de l'activité plaquettaires, ainsi qu'une prolongation du temps de saignement.

Nov 5, 2020 · To study the impact of thrombocytopenia on bleeding with APT, we used intravital imaging in a murine hemostasis model and adoptive platelet transfer to generate mice with …

Sep 26, 2023 · Drugs taken to reduce the risk of blood clotting can increase the risk of blood in the urine (called hematuria) and medical expenses for treatment. Drug-drug interactions are a …

May 1, 2024 · Anticoagulants and antiplatelet drugs are risk factors for gross hematuria (GH). Moreover, co-medication and drug-drug interactions (DDIs) may influence GH and its clinical …

Among enteral and parenteral anticoagulant and antiplatelet medications studied, enoxaparin is associated with the highest rates of hematuria-related events. Further work is needed to …

Coagulation disorders in critically ill patients presenting with bleeding can be multicausal. The drugs applied can interfere and impair the coagulation cascade. Point-of-care (POC) …

Apr 3, 2025 · Idiopathic Thrombocytopenic Purpura (ITP) with renal involvement: This condition primarily affects platelets but can have associated renal manifestations, including microscopic …

Normally, an increased platelet count increases the risk of thrombotic events, while a decreased platelet count increases the risk of bleeding. However, ET is a disease that presents with …

Mar 31, 2020 · Therefore, through this case, we highlight the importance of platelet counts remaining stable when a patient with HIT is treated with apixaban.